Page 415 - شرور شركات الأدوية

‫ﻣﻼﺣﻈﺎت‬

(19) Stafford RS, Wagner TH, Lavori PW. New, but Not Improved?
Incorporating Comparative-Effectiveness Information into FDA Labeling.
N Engl J Med. 2009 Aug 12;NEJMp0906490.

(20) Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno
D, Barker AH, et al. Mortality and morbidity in patients receiving encainide,
flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl
J Med. 1991 Mar;324(12):781–788.

(21) ALLHAT Collaborative Research Group. Major cardiovascular
events in hypertensive patients randomized to doxazosin vs chlorthali-
done: the antihypertensive and lipid-lowering treatment to prevent heart
attack trial (ALLHAT). JAMA. 2000 Apr;283(15):1967–1975.

(22) Lenzer J. Spin doctors soft pedal data on antihypertensives. BMJ.
2003 Jan 18;326(7381):170.

(23) Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects
of glucagon-like peptide-1 receptor agonists on weight loss: systematic
review and meta-analyses of randomised controlled trials. BMJ. 2012 Jan
11;344(jan10 2):d7771-d7771.

(24) Grimes DA, Schulz KF. Surrogate end points in clinical research:
hazardous to your health. Obstet Gynecol 2005;105:1114–8.

(25) This graph is from Chapter 7 of an excellent (though long and
serious) history of the FDA: Carpenter D. Reputation and Power: Organi-
zational Image and Pharmaceutical Regulation at the FDA. Princeton Uni-
versity Press; 2010.

(26) Mitka M. FDA Takes Slow Road Toward Withdrawal of Drug Ap-
proved With Fast-Track Process. JAMA. 2011 Mar 9;305(10):982–4.

(27) Press Announcements > FDA Proposes Withdrawal of Low Blood
Pressure Drug [Internet]. [cited 2012 May 7]. Available from: http://www
.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm222580.htm.

415